PubMed is a service of the U.S. National Library of Medicine that includes citations and abstracts (if available) from MEDLINE and other life science journals back to 1948.
Pub Med Central is the U.S. National Library of Medicine’s digital archive of biomedical and life sciences journal literature, providing free access to the full text of articles.
Clinical Trial Toolbox
Code of Federal Regulations (CFR)
The CFRs are the rules for the United States organized by Title. Title 21 is specific to Food and Drug law and is split into parts ranging from electronic records (Part 11), human subject protection (Part 50), investigational new drug applications(Part 312) to orphan drugs (Part 316). Search CFR Title 21.
The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
The ICH is made up of representatives from regulatory agencies in the United States, Japan and Europe and representatives from the pharmaceutical industry. The ICH has developed multiple guidelines that recommend a streamlined process in the drug development, testing and marketing process. ICH guidelines.
- E6 Good Clinical Practice (GCP) document is the guidance developed by ICH for participating in clinical trials.
Investigational New Drug (IND) Application.
An IND application is required for the study of any non marketed drug and for any marketed drug used off label in a clinical trial.
- 1572 FDA Information Sheet states requirements for completing the 1572 (updated May 2010)
This site provides information on federal and privately funded clinical trials.
Common Terminology Criteria for Adverse Events
The CTCAE is an adverse event (AE) coding system developed for oncology trials by the National Cancer Institute. The MSG uses this coding system in some of its trials to standardize AE coding.
CINCH (Clinical Investigation of Neurologic Channelopathies Consortium) CINCH is a collaborative effort of doctors, patient organizations, and federal health agencies that want to learn more about these diseases so that ultimately they can offer better treatments to patients.
NEALS (The Northeast Amyotrophic Lateral Sclerosis Consortium)
PNCR (Pediatric Neuromuscular Clinical Research Network)
The PNCR Network brings together outstanding clinical investigators at four leading academic institutions in the Northeast and provides an opportunity for patients with SMA in this region of the United States to actively participate as research participants in a search for the cure of this devastating childhood motor neuron disease.
The Fields Center
The Fields Center seeks to provide individuals with FSHD and their families with useful information about FSHD.
TREAT-NMD is a network for people with neuromuscular diseases and professionals working in the field.
BIO-NMD is an EU funded project which bridges basic research and clinical research with the aim of discovering and validating biomarkers for neuromuscular disease.
Dysimmune Diseases Foundation (DDF) Young Investigator Research Grant
July 30, 2020
Dysimmune Diseases Foundation (DDF) is proud to announce the first Young Investigator Research Grant which will provide $75,000 to support autoimmune neuromuscular disease clinical research.
Dysimmune Diseases Foundation (DDF) was created in 2005 as a non-profit health foundation. Our goals are: to support access to treatment for patients with autoimmune disorders, to foster support for patients, families, and physicians through advocacy for autoimmune disease research and treatments, and to fund research into the cause, treatment, and cure for autoimmune diseases with a focus on neuromuscular autoimmune diseases
Deadline: Letters of intent accepted August 15, 2020 – 11:59 PM EST October 1, 2020.
What: DDF Young Investigator Research Grant
Purpose: To support the autoimmune neuromuscular disease research of investigators in the early stages of their career.
Eligibility: To be eligible for a grant, an applicant must: hold a Doctor of Medicine (M.D.), or equivalent degree (i.e. D.O.), not be beyond Assistant Professor level and not more than five years post-fellowship (extenuating circumstances will be considered), be qualified to conduct a program of original research independently or under the supervision of a Principal Investigator, have an acceptable research plan for a specific autoimmune neuromuscular disease, have access to institutional resources necessary to conduct the proposed research project, and have a designated mentor for research guidance. Proposals from applicants working at institutions outside the United States will not be considered.
Budget and Project Period: $75,000 will be granted over two years to cover direct costs of research and/or provide partial salary support.
Submission: Website with grant details and guidelines will be shared August 15, 2020. Candidates will be invited to submit full proposals on November 1, 2020, proposals will be due February 1, 2021. Grant award will be announced April 1, 2021.
TMA Research Grant Program – TMA offers research funding for immune-mediated myositis
The Myositis Association recognizes that the myositis patient’s best hope for a cure lies in scientific research to develop a better understanding of myositis diseases, find better treatments, and, ultimately, discover a cure for all forms of myositis.
TMA is currently seeking applications for pilot funding and fellowship grants for promising myositis research projects.
Mentored Research Fellowships
• Designed to support projects from junior investigators (MDs and PhDs) commitment to the field of myositis
• Salary support for up to $50,000 per year for 2 years
Pilot Project Grants
• Funding for new and innovative research projects with goal to attract future funding from other sources (such as NIH)
• Awarded for 1-2 years to a maximum of $100,000 annually
More information on the TMA Research Grant Program
Muscular Dystrophy Association
MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.
Food and Drug Administration
The FDA Office of Orphan Products Development’s (OOPD) mission is to assist and encourage the identification, development, and availability of safe and effective products for people with rare diseases/disorders. The OOPD administers the major provisions of the Orphan Drug Act (ODA) which provide incentives for sponsors to develop products for rare diseases, usually defined as affecting fewer than 200,000 people in the United States.
National Institutes of Health
NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability.
- NINDS – The mission of NINDS is to reduce the burden of neurological disease – a burden borne by every age group, by every segment of society, by people all over the world.
- NIAMS – The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases, the training of basic and clinical scientists to carry out this research, and the dissemination of information on research progress in these diseases.
The Congressionally Directed Medical Research Programs (CDMRP) was initiated by a Congressional appropriation to foster novel approaches to biomedical research in response to the expressed needs of its stakeholders – the American public, the military, and Congress. The CDMRP fills research gaps by funding high impact, high risk and high gain projects that other agencies may not venture to fund. While individual programs are unique in their focus, all of the programs managed by the CDMRP share the common goal of advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. The CDMRP strives to transform healthcare for Service Members and the American public through innovative and impactful research.
ALSRP – The mission for the ALSRP is to fund innovative and impactful research to develop new treatments for ALS.
DMDRP – The mission for the DMDRP is to better support discovery and development of therapeutics, devices, and other interventions, and to promote their rigorous clinical testing.
PRMRP – The mission for the PRMRP is to encourage, identify, select, and manage medical research projects of clear scientific merit and direct relevance to military health. The PRMRP is committed to supporting research that has the potential to profoundly impact the development and implementation of medical devices, drugs, and clinical guidance that will enhance the precision and efficacy of prevention, diagnosis, and treatment across a wide range of disciplines including autoimmune diseases and immunology, cardiovascular health, endocrine health and metabolism, environmental health, infectious diseases, internal medicine, neurological and psychological health, orthopedic and regenerative medicine, and respiratory health and injury.